STAT3-Driven Upregulation of TLR2 Promotes Gastric Tumorigenesis Independent of Tumor Inflammation  by Tye, Hazel et al.
Cancer Cell
ArticleSTAT3-Driven Upregulation
of TLR2 Promotes Gastric Tumorigenesis
Independent of Tumor Inflammation
Hazel Tye,1 Catherine L. Kennedy,1 Meri Najdovska,1 Louise McLeod,1 William McCormack,3 Norman Hughes,4
Anouk Dev,2 William Sievert,2 Chia Huey Ooi,5 Tomo-o Ishikawa,6 Hiroko Oshima,6 Prithi S. Bhathal,4 Andrew E. Parker,3
Masanobu Oshima,6 Patrick Tan,5,7,8 and Brendan J. Jenkins1,*
1Centre for Innate Immunity and Infectious Diseases, Monash Institute of Medical Research
2Department of Medicine, Monash Medical Centre
Monash University, Clayton, Victoria 3168, Australia
3OPSONA Therapeutics, Ltd., Institute of Molecular Medicine, Trinity Centre for Health Sciences, St. James’ Hospital, Dublin 8, Ireland
4Department of Pathology, University of Melbourne, Footscray, Victoria 3011, Australia
5Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, 169857, Singapore
6Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa 920-1192, Japan
7Genome Institute of Singapore, 138672, Singapore
8Cancer Sciences Institute of Singapore, National University of Singapore, 117456, Singapore
*Correspondence: brendan.jenkins@monash.edu
http://dx.doi.org/10.1016/j.ccr.2012.08.010SUMMARYGastric cancer (GC) is associated with chronic inflammation; however, themolecular mechanisms promoting
tumorigenesis remain ill defined. Using a GCmousemodel driven by hyperactivation of the signal transducer
and activator of transcription (STAT)3 oncogene, we show that STAT3 directly upregulates the epithelial
expression of the inflammatory mediator Toll-like receptor (TLR)2 in gastric tumors. Genetic and therapeutic
targeting of TLR2 inhibited gastric tumorigenesis, but not inflammation, characterized by reduced prolifera-
tion and increased apoptosis of the gastric epithelium. Increased STAT3 pathway activation and TLR2
expression were also associated with poor GC patient survival. Collectively, our data reveal an unexpected
role for TLR2 in the oncogenic function of STAT3 that may represent a therapeutic target in GC.INTRODUCTION
Gastric cancer (GC) is the second most lethal cancer worldwide
(Parkin et al., 2005) and represents a growing number of cancers,
such as colon, lung, liver, and prostate, that are associated with
inflammation (Gao et al., 2005; Kawada et al., 2006; Ogata et al.,
2006; Walser et al., 2008). Although the molecular mechanisms
underlying the pathogenesis of these cancers remain unclear,
a causal correlation has been established between inflammation
triggered by microbes and gastrointestinal cancers, as evi-
denced by chronic gastritis caused by infection with the
Gram-negative pathogen Helicobacter pylori being a major risk
factor for human GC (Uemura et al., 2001).Significance
Hyperactivation of the STAT3 oncogene is a hallmark ofmany e
of actions by which STAT3 elicits its oncogenicity remains ill
STAT3 directly upregulates the expression of the innate immun
igenesis is associated with inflammation, we unexpectedly rev
proliferation rather than tumor inflammation. Given the emerge
various tumors also characterized by STAT3 hyperactivation (e
of TLR2 may provide a therapeutic approach to suppress tum
466 Cancer Cell 22, 466–478, October 16, 2012 ª2012 Elsevier Inc.The involvement of pathogenic microbes in gastrointestinal
inflammation and carcinogenesis has implicated Toll-like recep-
tors (TLRs), a key family of microbial sensors of the host innate
and adaptive immune systems (Kawai and Akira, 2010), in
mediating chronic inflammatory responses that promote tumor-
igenesis. For instance, genetic ablation of the common TLR and
interleukin (IL)-1 receptor family signaling adaptorMyD88 inmice
alleviates intestinal tumorigenesis induced in ApcMin/+ mice
(Rakoff-Nahoum and Medzhitov, 2007). With respect to human
gastric disease, TLR2 and TLR4 gene expression is elevated in
H. pylori-positive gastritis patients (Uno et al., 2007), and TLR2
and TLR4 gene polymorphisms are associated with an increased
GC risk (Hold et al., 2007; Tahara et al., 2007). However, thepithelial tumors, including gastric, however, the full spectrum
defined. We have discovered that in gastric epithelial cells,
e pathogen recognition receptor TLR2. While gastric tumor-
ealed that TLR2 promoted gastric epithelial cell survival and
nce of TLR signaling cascades as key oncogenic drivers in
.g., liver, colon), our studies suggest that selective blockade
origenesis.
Cancer Cell
TLR2 Promotes STAT3-Driven Gastric Tumorigenesisexpression status of these TLRs in human GC is unclear. In addi-
tion to the link between TLRs and the inflammatory response,
more recent studies have revealed that epithelial-expressed
TLRs can promote noninflammatory-related epithelial responses
including cell survival, proliferation and migration (Shaykhiev
et al., 2008), and angiogenesis (West et al., 2010). While these
findings constitute compelling circumstantial evidence for the
involvement of TLRs in GC and other inflammatory-related
cancers, a causal role for specific TLRs in these cancers remains
to be defined.
We have previously established the gp130F/F mouse, which by
6 weeks of age spontaneously develops gastric inflammation
and intestinal-type gastric tumors (Tebbutt et al., 2002). These
mice are homozygous for a knockin phenylalanine substitution
at tyrosine 757 in the cytoplasmic domain of the IL-6 cytokine
family receptor signaling subunit gp130, which disrupts the
negative feedback mechanism on gp130 signaling mediated
by suppressor of cytokine signaling (SOCS)3 (Tebbutt et al.,
2002). The gastric phenotype of gp130F/F mice is driven by
hyperactivation of the oncogenic latent transcription factor
STAT3 via the IL-6 cytokine family member, IL-11 (Ernst et al.,
2008; Jenkins et al., 2005), the clinical relevance of which is
underscored by upregulated IL-11 production and STAT3
hyperactivation being common traits of human GC (Ellmark
et al., 2006; Gong et al., 2005; Yakata et al., 2007).
Although the full spectrum of molecular mechanisms under-
lying the potent oncogenic properties of STAT3 in cancers
remains undetermined, the oncogenicity of STAT3 has been
attributed to, at least in part, its direct transcriptional upregula-
tion of genes, which promote angiogenesis, cell cycle progres-
sion, and cell survival (Bromberg et al., 1999). Moreover, the
complex role of STAT3 in cancer is evidenced by the fact
STAT3 can promote both a protumorigenic chronic inflammatory
microenvironment (Bollrath and Greten, 2009) and conversely
suppress antitumor innate and adaptive immune responses
(Kortylewski et al., 2005). Regarding the former, emerging
evidence invokes functional overlap between STAT3 and nuclear
factor-kB (NF-kB) oncogenic and inflammatory signaling path-
ways in driving inflammation-associated cancers (Bollrath and
Greten, 2009; Yang et al., 2007). Here, we investigate whether
crosstalk between STAT3 and TLR signaling contributes to the
molecular pathogenesis of GC.
RESULTS
Augmented TLR2 Expression in Gastric Tumors
Correlates with STAT3 Hyperactivation
We initially identified changes in the expression profile of genes
associated with the TLR network during gastric tumorigenesis
in gp130F/F mice by using RT2 Profiler PCR Arrays specific for
84 key TLR-associated genes. The majority of genes upregu-
lated in gastric antrum tumor tissue of 24-week-old gp130F/F
mice compared to tumor-free antrum tissue from gp130+/+
mice were NF-kB-regulated, including Tnfa and Il1b proinflam-
matory cytokine genes, as well as Tlr2, previously implicated
in human GC (El-Omar et al., 2003; Tahara et al., 2007) (Table
S1 available online). Independent quantitative real-time PCR
(qPCR) assays confirmed that among TLRs and other pattern
recognition receptors (PRRs) implicated in gastric disease,Cincluding Nod1 and Nod2 (Rosenstiel et al., 2006), only Tlr2
messenger RNA levels were significantly upregulated in
gp130F/F gastric tumor tissue compared to gastric tumor and
tumor-free tissue from gp130F/F:Stat3-/+ mice and gastric tumor-
free tissue from gp130F/F:Il11r/ mice displaying reduced
STAT3 activation (Ernst et al., 2008) and expression of STAT3-
target genes, Stat3 and Il11 (Figures 1A and S1A). In support
of the notion that TLR-induced responses are associated with
gastric tumorigenesis, the gastric expression of TLR-regulated
proinflammatory genes Il1b, Cxcl2, and Tnfa, as well as the
Cd14 gene encoding the coreceptor for TLR2 and TLR4, was
significantly increased in gp130F/F mice compared to compound
mutant mice (Figure S1A). The coexistent hyperactivation
of STAT3, augmented IL-11 expression, and specific upregula-
tion of TLR2 in gastric tumorigenesis was also independently
observed in the transgenic K19-Wnt/C2mE (Gan) mouse model
of GC that simultaneously overexpresses the cyclooxygenase-
2/prostaglandin E2 and Wnt signaling pathways in the gastric
mucosa (Itadani et al., 2009; Oshima et al., 2006) (Figures
S1B–S1E).
The augmented gastric expression profile of specific STAT3-
target genes and inflammatory mediators in gp130F/F mice
translated to human disease, since TLR2, IL1B, CD14, IL8
(human homolog of Cxcl2), STAT3, and IL11 were significantly
upregulated in tumor tissue from GC patients compared to
adjacent nontumor tissue and antrum tissue fromhealthy individ-
uals (Figure 1B). Furthermore, analysis of 78 primary human
gastric tumors (Ooi et al., 2009) revealed an overall positive
correlation between increased activation of the STAT3 pathway
and elevated TLR2 expression (Figure 1C). Among these 78
gastric tumors, we also compared 25 tumors in which STAT3
activation-TLR2 gene expression was high against 21 tumors
in which STAT3 activation-TLR2 expression was low. These 46
GC patients segregated into two distinct groups whereby those
displaying a combined high STAT3-TLR2 status had a sig-
nificantly impaired overall survival compared to patients with
a combined low STAT3-TLR2 status, thus suggesting that
STAT3 hyperactivation and TLR2 upregulation are poor prog-
nostic factors in GC (Figure 1D). In further support of a STAT3-
TLR2 axis in human GC, analysis of 18 human GC cell lines
previously characterized by gene expression signatures repre-
senting the activity status of various oncogenic pathways,
including STAT3 (Ooi et al., 2009), revealed a significant positive
correlation between the levels of STAT3 pathway activation and
TLR2 gene expression (Figure 1E).
STAT3-Mediated Upregulation of TLR2 in Gastric
Epithelial Cells
Since the gastric epithelium plays a key role in modulating the
immune response to microbes, we next evaluated whether
TLR2 was transcriptionally regulated by STAT3 in gastric epithe-
lial cells. Overexpression of the hyperactive STAT3-C mutant
(Bromberg et al., 1999) in mouse gastric epithelial IMGE-5
cells induced gene expression for Socs3, a known STAT3-target
gene (Table S2), and Tlr2, but not other TLR family members
(Figures 2A and 2B), and this result was also confirmed in
human GC epithelial cell lines MKN-28 and AGS (Figures 2C
and 2D). The transcriptional induction of TLR2 by STAT3-C
was further confirmed by the STAT3-C-driven transactivationancer Cell 22, 466–478, October 16, 2012 ª2012 Elsevier Inc. 467
Figure 1. Augmented STAT3 Activation
Correlates with Increased Expression of
TLR2 in Gastric Tumors of gp130F/F Mice
and Human GC
(A) qPCR expression analyses on antral gastric
tumor (T) or nontumor (NT) tissue of 24-week-old
mice of the indicated genotypes. Expression data
from at least five samples per genotype are shown
following normalization for 18S expression. *p <
0.05, **p < 0.01, and ***p < 0.001.
(B) qPCR of the indicated genes in human gastric
antral biopsies corresponding to normal (N) tissue
from healthy individuals (n = 6), as well as tumor (T)
and matched adjacent nontumor (NT) tissue from
GC patients (n = 12). Expression data are shown
following normalization for 18S. *p < 0.05, **p <
0.01, and ***p < 0.001.
(C) Top panel, STAT3 activation levels in 78
human gastric tumors and tumors with positive
STAT3 activation scores (STAT3 high), and those
with negative STAT3 activation scores (STAT3
low) are indicated by different color schemes.
Bottom panel, TLR2 gene expression levels in 78
tumors in the same order as the top panel. The y
axis values are presented on a log scale, with
positive and negative values representing high
and low TLR2 gene expression, respectively.
Spearman rank correlation coefficient (r) = 0.3395.
p = 0.0025.
(D) Kaplan-Meier survival analysis of a subset of
46 human GC patients with nonzero STAT3 acti-
vation scores stratified into two groups based on
either low (n = 21) or high (n = 25) combined
STAT3-TLR2 status.
(E) Correlation between STAT3 activation and
TLR2 expression in human GC cell lines. STAT3
activation levels in 18 human GC cell lines (-)
were determined based on the average STAT3
pathway activation scores (x axis). The y axis
represents the log2-transformed TLR2 gene
expression value. r = 0.6633, p = 3.86 3 105.
In (A and B), data are presented from replicate
analysis as the mean ± SEM. See also Figure S1
and Table S1.
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TLR2 Promotes STAT3-Driven Gastric Tumorigenesisof the full-length TLR2 promoter-luciferase reporter TLR2-2391
(Figure 2E). Moreover, bioinformatic analyses identified five
putative STAT3-binding sites in the 50 promoter region of
TLR2 (Figure 2F), and chromatin immunoprecipitation on either
IL-11-stimulated gastric epithelial cells or gp130F/F tumor tissue
revealed that tyrosine-phosphorylated (pY) STAT3 was recruited
to the TLR2 50 region spanning the putative STAT3 site at
bases 1241/1249 (Figures 2F–2H), thus suggesting that
TLR2 is a direct STAT3 target gene. In support of these data,
STAT3-C did not transactivate either the truncated (TLR2-
1248) or site-directed mutant (TLR2-TT > AA) TLR2-specific468 Cancer Cell 22, 466–478, October 16, 2012 ª2012 Elsevier Inc.promoter reporters that disrupted the
1241/1249 STAT3 site (Figure 2E).
The functional relevance of these findings
was validated by the augmented produc-
tion of IL-6 and IL-1b in primary gastric
epithelial cells from gp130F/F comparedto gp130+/+ mice stimulated with the TLR2 agonist Pam3Cys
(Figure S2A).
TLR2 Promotes Gastric Tumorigenesis in gp130F/F Mice
To genetically define a causal role for TLR2 in STAT3-driven gas-
tric tumorigenesis, we generated gp130F/F mice lacking TLR2
(gp130F/F:Tlr2/). The stomachs of 24-week-old gp130F/F:
Tlr2/ mice were noticeably smaller in size compared to those
of age-matched gp130F/F littermates (Figure 3A), analogous to
the reduced stomach size observed previously in gp130F/F:
Stat3-/+ mice due to suppression of STAT3-driven hyperplasia
Figure 2. STAT3 Directly Regulates
TLR2 Gene Expression in Gastric Epithelial
Cells
(A) qPCR of Socs3 and Tlr genes in gastric
epithelial IMGE-5 cells stably-transfected with
STAT3-C/green fluorescent protein (GFP) (+) or
GFP alone (). Data from three independent
experiments are shown following normalization for
18S. *p < 0.05. Cell lysates were immunoblotted
with STAT3 and actin antibodies with exogenous
STAT3-C/GFP fusion protein (120kDa) detected
in transfected cells only.
(B) qPCR of endogenous Tlr2 and Tlr4 gene
expression in IMGE-5 cells transiently-transfected
with increasing amounts of STAT3-C/GFP. Data
from three independent experiments are shown
following normalization for 18S. *p < 0.05 versus
cells transfected with GFP alone.
(C and D) qPCR of endogenous gene expression
for TLR family members and STAT3 in human
MKN-28 (C) and AGS (D) cells transiently-trans-
fected with 500ng STAT3-C/GFP or GFP alone.
Data from four independent experiments are
shown for each cell line following normalization for
ACTIN. *p < 0.05.
(E) Human epithelial 293 cells were cotransfected
with luciferase reporter plasmids for the full-
length TLR2 promoter (TLR2-2391), the truncated
TLR2 promoter (TLR2-1248), and the site-
directed mutant TLR2 promoter (TLR2-TT > AA)
together with the STAT3-C/GFP construct or an
empty GFP vector (GFP). Data from four inde-
pendent experiments are expressed as the mean ± SEM-fold change relative to TK-renilla normalized reporter activity in GFP-transfected cells. **p < 0.01.
(F) Schematic diagram of the TLR2 gene promoter. The vertical arrow indicates where the TLR2 promoter fragment was truncated in the TLR2-1248 construct
and the underlined ‘‘TT’’ bases at the 1241/1248 STAT3 site (bold type) were mutated to ‘‘AA’’ in the TLR2-TT > AA construct. Arrowheads depict primers
(used in ChIP assays) spanning five putative STAT3 binding sites in the TLR2 promoter.
(G) Cells were incubated without or with IL-11 for 1 hr and subjected to ChIP assays using pY-STAT3 or IgG isotype control antibodies. The graph represents
quantification by qPCR of the immunoprecipitated TLR2 promoter fragment containing the 1241/1248 STAT3 site bound to each antibody. Data from
four independent experiments are expressed as the mean ± SEM % of input DNA. Gels represent semiquantitative PCR of specific promoter fragments that
were amplified from coprecipitated DNA from IL-11-treated cells using primers spanning the 1241 STAT3 site in the TLR2 promoter (F) and, as a control, the
STAT3 binding site at position 70 in the SOCS3 promoter.
(H) Gel representing semiquantitative PCR of ChIP assay for pY-STAT3 interaction with the TLR2 gene promoter as per (G), except on gastric tumor tissue
from gp130F/F mice.
In (A)–(D), all data are presented from replicate analysis as the mean ± SEM-fold induction relative to cells transfected with GFP alone. See also Figure S2 and
Table S2.
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TLR2 Promotes STAT3-Driven Gastric Tumorigenesisthroughout the gastric epithelium (Jenkins et al., 2005). The
reduction in stomach size and mass of gp130F/F:Tlr2/ mice
was more pronounced in males (50% reduction in mass) than
females (30%) when compared to their gp130F/F counterparts
(Figures 3A and 3B). The gastric tumor mass of gp130F/F:Tlr2/
mice was also significantly reduced (70% in male and 40% in
female) compared to gp130
F/F
mice of the corresponding sex
(Figure 3C). The total incidence of gastric lesions in gp130F/F:
Tlr2/ male (2.76 ± 0.28) and gp130F/F:Tlr2/ female (4.22 ±
0.76) mice was also lower than in gp130F/F males (8.30 ± 0.49)
and gp130F/F females (7.50 ± 1.22), with a noticeable reduction
in the numbers of large (>4 mm diameter) tumors (Figure 3D).
We also note that STAT3 tyrosine phosphorylation and IL-11
expression levels in gp130F/F:Tlr2/ tumors remained elevated
and were comparable to those of gp130F/F gastric tumors (Ernst
et al., 2008) (Figures 3E and 3F), consistent with the IL-11/STAT3
signaling axis being an upstream regulator of TLR2. The patho-
logical requirement for TLR2 in gastric tumorigenesis was
specific, since the gross appearance of stomachs and extentCof gastric tumorigenesis in gp130F/F:Tlr4/ male and female
mice were comparable to those of gp130F/F littermates (Figures
S2B–2F).
TLR2 Promotes Gastric Epithelial Cell Survival
and Proliferation, but Not Inflammation
We have previously reported that gastric tumor formation in
gp130F/F mice is characterized by chronic inflammatory cell
(lymphoplasmacytoid) aggregates in the submucosa (Ernst
et al., 2008). However, despite reduced gastric tumorigenesis
in gp130F/F:Tlr2/ mice, histological examination of hematox-
ylin and eosin (H&E)-stained gastric sections from 24-week-
old mice indicated that the extent of these submucosal
inflammatory aggregates was comparable to that of gp130F/F
mice (Figure 3G). Further histological and immunohistochem-
ical analyses revealed a similar composition of both innate
and adaptive inflammatory cell infiltrates between the two
genotypes (Figures S3A–S3C). These observations were further
verified by flow cytometry, which indicated comparableancer Cell 22, 466–478, October 16, 2012 ª2012 Elsevier Inc. 469
Figure 3. Alleviation of Gastric Tumor
Formation, but Not Inflammation or STAT3
Hyperactivation, in gp130F/F Mice Lacking
TLR2
(A) Representative appearance of stomachs from
24-week-old male (M) and female (F) mice of the
indicated genotypes. Arrows indicate macro-
scopically visible tumors >4 mm in diameter.
Fundic (f) and antral (a) stomach regions are
labeled.
(B–D) Scatter plots depicting the total mass
(grams) of stomachs (B) and gastric tumors (C), as
well as the incidence of tumors (D), from either
male or female gp130F/F and gp130F/F:Tlr2/ 24-
week-old mice. Data for each genotype are ex-
pressed as the mean ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001.
(E) Western blots of gastric tumor lysates from 24-
week-old gp130F/F and gp130F/F:Tlr2/mice with
the indicated antibodies.
(F) Top panels: Representative photomicrographs
showing immunohistochemistry for tyrosine-
phosphorylated STAT3 in the surface epithelium of
gastric tumors of 24-week-old gp130F/F and
gp130F/F:Tlr2/ mice. Scale bars = 200 mm.
Bottom panels: Representative photomicrographs
showing pY-STAT3+ cells in the mucosal epithe-
lium (m) and submucosa (sm) containing inflam-
matory cells in gp130F/F and gp130F/F:Tlr2/
mice. Scale bars = 200 mm.
(G) Representative photomicrographs showing
H&E-stained cross-sections through the antral
region of stomachs from 24-week-old mice of the
indicated genotypes. Arrows point to patches of
inflammatory cell accumulates in the gastric
submucosa of gp130F/F and gp130F/F:Tlr2/mice
under low power magnification. Scale bars =
200 mm.
See also Figure S3.
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TLR2 Promotes STAT3-Driven Gastric Tumorigenesisfrequencies of Gr-1+CD11b+ (myeloid-derived suppressor cells
[MDSC]), CD11b+F4/80+ (monocytes/macrophages), B220+ (B),
and CD3+ (T) cells in the stomachs and perigastric lymph nodes
of gp130F/F and gp130F/F:Tlr2/ mice (Figures S3D and S3E).
In addition, the activation status of B (B220+CD86+) and
T (CD4+CD69+ and CD8+CD69+) cells, which are the predomi-
nant gastric tumor-infiltrating immune cells in gp130F/F and
gp130F/F:Tlr2/ mice, in the stomach and perigastric lymph
node tissue of the two genotypes was comparable (Figure S3F),
as were the percentages of TNFa- or IFNg-producing gastric or
perigastric lymph node lymphocytes (Figure S3F). Despite
these observations supporting the notion that TLR2 does not
promote the activation of these inflammatory cells, the expres-
sion of a subset of TLR2-regulated cytokines and chemokines470 Cancer Cell 22, 466–478, October 16, 2012 ª2012 Elsevier Inc.was reduced in gp130F/F:Tlr2/ gastric
tumors (Figure S3G), as well as in gastric
epithelial cells from gp130F/F:Tlr2/
mice stimulated with microbial-contain-
ing gastric gp130F/F homogenates (Fig-
ure S3H), thus confirming the reduced
TLR2 responsiveness of the gastric
epithelium in gp130F/F:Tlr2/ mice.
These data therefore suggest that gastric epithelial stimulation
by TLR2 does not promote the infiltration or activation of
inflammatory cells.
We next investigated whether the reduced gastric tumorigen-
esis in gp130F/F:Tlr2/ mice correlated with any proliferative,
apoptotic, and/or angiogenic changes within the gastric
mucosa. By contrast to the expansion of proliferating gastric
cells observed throughout the mucosal epithelium of gp130F/F
mice, the proliferation zone in the gastric epithelium of
gp130F/F:Tlr2/ mice was more defined and resembled that
of gp130+/+ mice with no apparent proliferating-cell nuclear
antigen (PCNA)-positive staining in the surface epithelium
(Figures 4A and 4B). Furthermore, apoptotic TUNEL-positive
cells were found predominantly within the surface gastric
Cancer Cell
TLR2 Promotes STAT3-Driven Gastric Tumorigenesisepithelial region of gp130F/F:Tlr2/ mice, whereas little to no
TUNEL-positive gastric cells were detected within the mucosal
epithelium of gp130F/F mice (Figure 4C). The extent of cellular
proliferation and apoptosis within the gastric submucosal
inflammatory cell infiltrates, however, was similar between
gp130F/F and gp130F/F:Tlr2/ mice (Figures S4A and S4B).
With respect to angiogenesis, the expression of the CD31
angiogenic marker in the gastric mucosa and submucosa of
gp130F/F and gp130F/F:Tlr2/ tumors was comparable (Figures
S4C and S4D). Collectively, these results unexpectedly suggest
that TLR2 promotes gastric epithelial cell growth rather than
gastric tumor inflammation or angiogenesis.
The notion that TLR2 signaling can promote cell proliferation
was also confirmed in two human GC epithelial cell lines,
whereby TLR2 ligand stimulation of MKN-28 and NUGC4 cells
resulted in a dose-dependent significant increase in cell pro-
liferation (Figure 4D). TLR2 ligand stimulation of these human
GC cell lines also significantly upregulated the expression of
numerous cell cycle progression and cell survival/antiapoptosis
genes (Figures 4E and 4F), amongwhichCCND2, BCL2A1, IER3,
and BIRC3 are highly expressed in human GC (Li et al., 2011;
Park et al., 1997; Sasada et al., 2004; Takano et al., 2000). These
observations were also supported in vivo in the gp130F/F tumor
model, where the expression of these cell survival and cell cycle
progression genes was significantly reduced in gp130F/F:Tlr2/
tumors compared to gp130F/F tumors (Figure 4G).
To identify signaling pathways that facilitated the TLR2 ligand-
induced proliferation of human GC cells, cells were pretreated
with a series of well-documented signaling pathway inhibitors
at doses shown to suppress the TLR2-driven activation of
NF-kB; phosphatidylinositol 3-kinase (PI3K)/Akt; stress-acti-
vated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK);
p38; and extracellular signal-related kinase (ERK)1/2 mitogen-
activated protein kinases (MAPKs) (Figure 5A). Suppression of
the PI3K/Akt, ERK1/2, and JNK MAPK, or NF-kB pathways
resulted in a significant inhibition of TLR2-stimulated cell
growth, whereas blocking the activity of p38 MAPK did not
impair TLR2-induced cell proliferation (Figure 5B). In support of
these findings, blockade of at least one of these known TLR2
signaling pathways in human GC cells significantly suppressed
the TLR2-induced expression of 6/8 cell cycle regulation and
survival genes (Figure 6A). These in vitro findings were also
validated in vivo, where treatment of gp130F/F mice with the
U0126 mitogen-activated protein/extracellular signal-regulated
kinase kinase (MEK) inhibitor suppressed the TLR2-induced
expression of Bcl2a1, Ccnd1, and c-Myc (Figures 6B and 6C).
Taken together, these results suggest that TLR2 utilizes multiple
signaling cascades to promote the growth of GC cells.
TLR2-Expressing Bone Marrow-Derived Inflammatory
Cells Do Not Promote Gastric Tumors
Wehave previously employed bonemarrow chimeras to demon-
strate that bone marrow-derived inflammatory cell infiltrates
displaying STAT3 hyperactivation do not contribute to gastric
inflammation-associated tumorigenesis (Ernst et al., 2008).
However, since TLR2 was expressed on both epithelial cells
(surface mucosa) and inflammatory cells (submucosa) in the
stomachs of gp130F/F mice (Figure 7A), we investigated whether
TLR2-expressing inflammatory cells played a role in gastricCtumorigenesis. Reconstitution of the hematopoietic compart-
ment of irradiated gp130F/F recipient mice with bone marrow
from donor gp130F/F:Tlr2/ mice (Figure S5A) did not alleviate
the size and number of gastric tumors, nor the overall size of
hyperplastic stomachs of the recipient mice (Figures 7B–7E).
Furthermore, the reciprocal reconstitution of gp130F/F:Tlr2/
recipient mice with gp130F/F donor bone marrow did not exacer-
bate gastric tumorigenesis (Figures S5B and S5C). As predicted,
gastric tumorigenesis and the overall appearance of stomachs
of control gp130F/F and gp130F/F:Tlr2/ recipient mice reconsti-
tutedwith autologous gp130F/F and gp130F/F:Tlr2/ donor bone
marrow, respectively, were indistinguishable from their naive
gp130F/F and gp130F/F:Tlr2/ counterparts (Figures 7B–7E).
Collectively, these data further support a role for gastric epithelial
TLR2-mediated responses in promoting tumorigenesis.
Therapeutic Targeting of TLR2 in gp130F/F Mice
Alleviates Gastric Tumorigenesis
To determine whether TLR2 may serve as a bona fide thera-
peutic target for GC, we next explored whether therapeutic
suppression of TLR2 activity would alleviate the growth of estab-
lished gastric tumors in gp130F/F mice. We initially examined
the efficacy of the OPN-301 TLR2 blocking antibody (Meng
et al., 2004) in suppressing acute TLR2-driven gastric responses
by pretreating gp130F/F mice by intraperitoneal (i.p.) injection
with OPN-301 antibody or isotype control for 30 min prior to
administration with Pam3Cys over 6 hr. qPCR confirmed that
OPN-301 significantly suppressed the TLR2-dependent induc-
tion of Cxcl2 and Tnfa genes in gastric antrum tissue (Figure 8A).
Since the onset of gastric hyperplasia and tumors in gp130F/F
mice occurs from 4–6 weeks of age and progresses in severity
up to 24 weeks of age (Jenkins et al., 2005; Tebbutt et al.,
2002), we undertook a therapeutic approach by injecting 12-
week-old gp130F/F mice displaying established gastric disease
with OPN-301 or isotype control twice weekly over 10 weeks.
Notably, OPN-301 treatment substantially reduced the stomach
size and overall tumor burden, including the number of gastric
tumors, of gp130F/F mice (Figures 8B–8D). Collectively, these
data demonstrate that therapeutic targeting of TLR2 suppresses
both the initiation and growth of gastric tumors in gp130F/F mice.
DISCUSSION
Here, we reveal that uncontrolled activation of the oncogenic
transcription factor STAT3 promotes gastric tumorigenesis
through the specific upregulation of TLR2 in the gastric epithe-
lium. Surprisingly, the composition and activation status of
gastric inflammatory cell infiltrates in tumors of gp130F/F mice
was comparable in the presence or absence of TLR2, suggesting
that TLR2 signaling does not contribute to tumor-associated
gastric inflammation. Rather, we observed that TLR2 promoted
cell survival and proliferation in the mouse gastric tumor epithe-
lium. Furthermore, our bone marrow reconstitution studies imply
a protumorigenic role for TLR2 in a tumor-cell intrinsic rather than
extrinsic (i.e., inflammatory cell) manner, consistent with our
previous data for STAT3 (Ernst et al., 2008). A role for the
STAT3-TLR2 axis in gastric tumorigenesis is also supported by
the comparable reductions observed in both stomach size and
tumor mass upon either ablation of TLR2 or genetically reducingancer Cell 22, 466–478, October 16, 2012 ª2012 Elsevier Inc. 471
Figure 4. TLR2 Promotes Gastric Epithelial Tumor Cell Survival and Proliferation
(A and B) Representative photomicrographs showing PCNA-stained cross-sections under low power (A) and high power (B) magnification through the antral
region of stomachs from 24-week-old mice of the indicated genotypes. In (A), arrows point to the defined zone of proliferating mucous neck cells of the gastric
epithelium. Scale bars = 100 mm.
(C) Representative photomicrographs of TUNEL-stained cross-sections through the antral stomach region from mice of the indicated genotypes. Scale bars =
100 mm.
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Figure 5. TLR2-Driven Cell Proliferation in
Human GC Cells Occurs via Activation of
Multiple Signaling Pathways
(A) Representative western blots with the indicated
antibodies of lysates from MKN-28 cells pre-
treated with DMSO vehicle or specific pathway
inhibitors at the indicated concentrations for
30min, and thenstimulatedwithout orwith10mg/ml
Pam3Cys for 30 min. Densitometry quantifica-
tion from two independent experiments for the
indicated phosphorylated signaling molecules
and relative expression was determined against
the corresponding amount of total protein and is
presented as the mean ± SD.
(B) Proliferative response of MKN-28 cells incu-
bated over 24 hr without () or with (+) Pam3Cys
(10 mg/ml) in the presence of pathway inhibitors for
PI3K (Wortmannin), ERK MAPK (U0126), JNK
MAPK (SP600125), NF-kB (MG132), and p38
MAPK (SB203580). Data are from four indepen-
dent experiments in which cells were pretreated
for 30 min with either DMSO vehicle () or the
indicated concentrations of specific inhibitors
(Inhib) and are expressed as the mean ± SEM %
increase in proliferation relative to DMSO pre-
treated cells in the absence of Pam3Cys. *p < 0.05,
**p < 0.01, and **p < 0.001 versus Pam3Cys-
incubated cells pretreated with DMSO.
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diminishes the STAT3-driven hyperplastic response throughout
the entire gastric epithelium (Jenkins et al., 2005). Collectively,
our findings not only support emerging evidence for a broader
role of TLRs in regulating noninflammatory processes, including
epithelial cell proliferation and survival (Shaykhiev et al., 2008),
but also demonstrate in a STAT3-driven cancer model that
TLR2 is required for tumorigenesis in a cell autonomous manner
independently of inflammation.
Another key finding of our current study was that TLR2 stimu-
lation promoted the proliferation of human gastric epithelial
(cancer) cells, as well as the transcriptional induction of
numerous genes associated with cell cycle regulation and antia-
poptosis, via multiple downstream signaling pathways, namely
PI3K/Akt, ERK1/2 and JNK MAPKs, and NF-kB. The notion
that these signaling pathways represent an important mecha-(D) Proliferative response of human MKN-28 and NUGC4 cells to the TLR2 ligand Pam3Cys over 24 hr. Data
which cells were either untreated or treated with the indicated concentrations of Pam3Cys, and are express
relative to untreated cells. *p < 0.05, **p < 0.01, ***p < 0.001.
(E and F) qPCR gene expression analyses in MKN-28 (E) and NUGC4 (F) cells stimulated (+) with TLR2 ligand
three independent experiments are shown following normalization for ACTIN. *p < 0.05, **p < 0.01, ***p < 0.
(G) qPCR gene expression analyses in antral gastric tumor tissue of 24-week-old gp130F/F (n = 5) and gp130
following normalization for 18S. *p < 0.05, **p < 0.01.
In (E)–(G), data are presented from replicate analysis as the mean ± SEM. See also Figure S4.
Cancer Cell 22, 466–478,nism promoting gastric epithelial cell
growth is supported by previous observa-
tions that blockade of either the PI3K/Akt,
ERK1/2 MAPK, or NF-kB pathways,
which are frequently overexpressed
and/or overactivated in human GC (Cintiet al., 2008; Liang et al., 2005; Sasaki et al., 2001), in human
GC cell lines suppresses cell proliferation (Asciutti et al., 2011;
Lim et al., 2001; Yokota et al., 2010). We also note that a role
for the PI3K/Akt pathway in the TLR2-induced survival of
epithelial cells has been previously reported (Cario et al.,
2007). Furthermore, several of these antiapoptotic and cell
proliferation genes (e.g., BCL2A1, BIRC3) have previously
been reported to be highly expressed in human GC (Li
et al., 2011; Park et al., 1997; Sasada et al., 2004; Takano
et al., 2000). We note that despite a subset of these genes,
such as CCND1 and C-MYC, being STAT3-regulated genes
(Bromberg et al., 1999; Ernst et al., 2008), their reduced expres-
sion in tumors of gp130F/F:Tlr2/ versus gp130F/F mice occurs
despite comparable STAT3 hyperactivation in tumors from
both genotypes. Such a discrepancy can be reconciled by the
complex transcriptional regulation of these genes by bothare from at least three independent experiments in
ed as the mean ± SEM % increase in proliferation
(100 ng/ml) for 6 hr. Expression data from at least
001 versus untreated () cells.
F/F:Tlr2/ (n = 5) mice. Expression data are shown
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Figure 6. TLR2 Upregulates the Expression
of Cell Cycle Regulation and Survival Genes
in Human GC Cells via Multiple Signaling
Pathways
(A) qPCR gene expression analyses in MKN-28
cells pretreated for 30 min with either DMSO
vehicle (black bars; ) or specific inhibitors (gray
bars) and stimulated with TLR2 ligand (100 ng/ml)
for 6 hr. Expression data from three independent
experiments are shown following normalization for
ACTIN and are presented as the mean ± SEM %
relative to DMSO pretreated cells stimulated with
TLR2 ligands. *p < 0.05, **p < 0.01, and ***p <
0.001 versus TLR2 ligand-stimulated cells pre-
treated with DMSO. Wn, Wortmannin; U0, U0126;
SP, SP600125; MG, MG132.
(B and C) qPCR gene expression analyses in
gastric tumor tissue from gp130F/F (F/F) mice that
were either untreated (, white bars) or treated
with MEK inhibitor U0126 for 18 hr (U0, gray bars)
(B) and either untreated (, white bars), adminis-
tered with Pam3Cys over 6 hr (P3C, black bars), or
pretreated with U0126 for 18 hr prior to adminis-
tration with Pam3Cys for 6 hr (U0 + P3C, gray bars)
(C). Expression data from at least three samples
per treatment group are shown following normali-
zation for 18S and are presented from replicate
analysis as the mean ± SEM fold induction. *p <
0.05, **p < 0.01, and ***p < 0.001.
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latter of which have been widely reported for CCND1 and
C-MYC to involve transcriptional regulatory factors such as
NF-kB, activating transcription factor 2, activator protein 1,
and cAMP response element-binding (Beier et al., 1999; Boulon
et al., 2002; Joyce et al., 1999; Kim et al., 2000; Vartanian
et al., 2011). Since these transcription factors are also activated
by TLR2 (Kawai and Akira, 2006; Mellett et al., 2011; Wang
et al., 2011), the reduced gene expression in gp130F/F:Tlr2/
gastric tumors may be a consequence of, at least in part, the
loss of gastric TLR2-mediated activation of such transcription
factors.
Several recent studies support a role for TLR2 in promoting
tumorigenesis, albeit by divergent mechanisms, which most
likely reflect the complex role of TLR2 in innate and adaptive
immunity, as well as nonimmune (e.g., epithelial) cellular
responses. For instance, TLR2-dependent NF-kB signaling has
been associated with WEHI-3B tumor cell survival and disease
progression in an in vivo mouse model of myelomonocytic
leukemia (Shcheblyakov et al., 2011). In addition, TLR2 can
promote the proliferation of hepatocarcinoma tumor cells in a
bacterial (Listera monocytogenes) infection-associated ectopic
tumor model independent of influencing immunosuppressive
immune cells (e.g., MDSC) (Huang et al., 2007). By contrast, in
another ectopic tumor model involving metastatic melanoma
cells, it was proposed that TLR2 promoted tumor metastasis
via STAT3 activation leading to suppression of antitumor
immunity (Yang et al., 2009), an oncogenic mechanism previ-
ously assigned to STAT3 (Kortylewski et al., 2005). However,
the role of TLR2 in STAT3-mediated gastric tumorigenesis is
unlikely to involve such a mechanism; since we have previously474 Cancer Cell 22, 466–478, October 16, 2012 ª2012 Elsevier Inc.demonstrated that gastric tumorigenesis in gp130F/F mice is
independent of antitumor immunity (Ernst et al., 2008). Further-
more, we demonstrate here that gastric STAT3 hyperactivation
in gp130F/F mice is unaffected by targeting TLR2, and bone
marrow reconstitution studies confirm that gastric tumor growth
is independent of TLR2 expression on hematopoietic-derived
tumor-infiltrating immune cells.
While our current study demonstrates a causal role for TLR2
in gastric tumorigenesis, the role of TLRs in other inflammation-
associated cancers, in particular colon, is controversial. For
instance, our work presented here builds upon recent reports
that the MyD88 adaptor protein, which is essential for TLR
signaling, promotes intestinal tumorigenesis (Rakoff-Nahoum
and Medzhitov, 2007; Schiechl et al., 2011). Similar to our
current findings for gastric tumorigenesis, reduced intestinal
tumor formation in MyD88-deficient ApcMin/+ mice was associ-
ated with higher numbers of apoptotic tumor cells without any
change in the frequency of infiltrating leukocytes (Rakoff-
Nahoum and Medzhitov, 2007). In addition, MyD88-deficiency
protected mice from colonic tumor development but not inflam-
mation in a colitis-associated colorectal cancer (CAC) model
induced by oxazolone and azoxymethane (AOM) (Schiechl
et al., 2011). On the other hand, others have reported that
Myd88/ mice are more susceptible to AOM/dextran sodium
sulfate (DSS) CAC (Salcedo et al., 2010). The contrasting roles
for TLR2 in CAC induced by AOM/DSS have also been re-
ported, with one study suggesting that TLR2 is dispensable
for colonic tumorigenesis (Salcedo et al., 2010), whereas
another that tumorigenesis was exacerbated in Tlr2/ mice
(Lowe et al., 2010). Collectively, these discrepancies most likely
reflect inherent differences in the experimental approaches
Figure 7. TLR2-Mediated Gastric Tumorigenesis Is Independent of
Bone Marrow-Derived Inflammatory Cells
(A) Representative TLR2-stained cross-sections through the antral stomach
tumor region of a 24-week-old gp130F/F mouse showing staining around the
surface area of the glandular gastric epithelium (left panel), as well as in
submucosal inflammatory cell infiltrates (right panel). Scale bars = 100 mm.
(B) Representative appearance of stomachs from 22-week-old gp130F/F
naive mice, or recipient gp130F/F mice reconstituted with autologous
gp130F/F (F/FF/F), or heterologous gp130F/F:Tlr2/ (F/FF/F:T2) donor bone-
marrow. a, antrum; f, fundus.
(C–E) Bar graphs depict the total mass (grams) of stomachs (C) and gastric
tumors (D) as well as the incidence of tumors (E) from the indicated mice. Data
for each group are expressed as themean ± SEM. gp130F/F, n = 3; F/FF/F, n = 3;
and F/FF/F:T2, n = 10.
See also Figure S5.
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carcinogenesis.
In summary, our current study defines that an endogenously
expressed PRR promotes gastric tumorigenesis by regulating
the expression of genes involved in cell survival and proliferation,
and importantly highlights the need to further investigate the
broader role of TLR2 in other inflammatory-related cancers, for
instance colon, prostate, and liver. In this regard, it is noteworthy
that deregulated STAT3 activation, including by gp130-acting
cytokines, has been linked to the pathogenesis of tumor forma-
tion in these organs (Bollrath et al., 2009; Gao et al., 2005;
Kawada et al., 2006; Ogata et al., 2006; Rebouissou et al.,
2009). Collectively, our findings that increased STAT3 activationCand TLR2 expression in human GC correlates with a poor prog-
nosis, together with the suppression of gastric tumorigenesis in
a STAT3-driven preclinical GC mouse model following genetic
and therapeutic targeting of TLR2, suggest that TLR2 represents
a compelling biomarker and therapeutic target for GC.
EXPERIMENTAL PROCEDURES
Human Gastric Biopsy Tissue Collection
Antral gastric biopsies were collected at Monash Medical Centre (Melbourne,
Australia) from 18 patients undergoing upper gastrointestinal endoscopy or
surgical resection for clinical indications. Patients with a history of taking
nonsteroidal anti-inflammatory drugs, proton pump inhibitors, or antibiotics
were excluded from the study. Biopsies were either snap-frozen in liquid
nitrogen or stored in 10% formalin, the latter for histopathological assessment
onH&E-stained tissue sections using the revised version of the Sydney System
(Dixon et al., 1996). Biopsies free of any lesions were considered normal. Full
and informed consent was obtained from all patients, and biopsy collection
was approved by the Southern Health Human Research Ethics Committee.
Mice and Treatments
The generation of gp130F/F, gp130F/F:Stat3+/, and gp130F/F:IL-11r/ mice
has been previously described (Ernst et al., 2008; Jenkins et al., 2005, Tebbutt
et al., 2002). Mice homozygous null for either Tlr2 (Takeuchi et al., 1999) or
Tlr4 (Hoshino et al., 1999) were used to generate gp130F/F:Tlr2/ and
gp130F/F:Tlr4/ mice. The specificity and pharmacokinetics of the OPN-301
monoclonal TLR2 blocking antibody (Opsona Therapeutics), analogous to
clone T2.5 (Meng et al., 2004), have been previously described (Arslan et al.,
2010). For acute studies, 12-week-old male gp130F/F mice were i.p. injected
with 10mg/kg of OPN-301 antibody or IgG1 isotype control for 30 min prior to
i.p. administration with 2mg/kg of Pam3Cys (EMC Microcollections) for 3 or
6 hr. For chronic studies, 12-week-old male gp130F/F mice were i.p. injected
with 10mg/kg of OPN-301 or IgG1 isotype control twice weekly over 10 weeks.
For treatment with the MEK 1/2 inhibitor U0126 (Cell Signaling Technology),
gp130F/F mice were i.p. injected with U0126 (10mg/kg) or vehicle (Dimethyl
sulfoxide; DMSO) for 18 hr prior to i.p. injection of Pam3Cys (2 mg/kg) for 6 hr.
All experiments were endorsed by the Monash University Animal Ethics
Committee and, where appropriate, included genetically-matched (mixed
129Sv 3 C57BL/6 background) gp130+/+ (wild-type) littermate controls.
Mice were housed under specific pathogen-free conditions and were age-
matched for each experiment.
Gastric Epithelial Cells
The generation of primary mouse gastric epithelial cells (Viala et al., 2004) and
maintenance of gastric IMGE-5, AGS, and MKN-28 cells (Jenkins et al., 2005)
have been described previously. Transfections of mouse IMGE-5 and human
MKN-28 and AGS cells were performed with the Nucleofector II System
(Amaxa) and FuGene-6 (Roche), respectively. Chromatin immunoprecipita-
tions were performed using the Imprint ChIP kit (Sigma-Aldrich) with
pTyr705-STAT3 and IgG antibodies (Santa Cruz Biotechnology). For experi-
ments involving the use of specific pathway inhibitors, cells were pretreated
for 30 min with either DMSO vehicle, U0126, the PI3K inhibitor Wortmannin
(Sigma), the NF-kB inhibitor MG132 (Calbiochem), the p38 MAPK inhibitor
SB203580 (Calbiochem), or the JNK MAPK inhibitor SP600125 (Calbiochem)
at the indicated concentrations prior to stimulation with Pam3Cys.
Statistical Analyses
All statistical analyses were performed using GraphPad Prism V5.0 software.
The normality of data was assessed using the D’Agostino and Pearson
omnibus K2 normality test. Statistical significance (p < 0.05) between the
means of two groups was determined using Student t tests (normal distribu-
tion) or Mann-Whitney U tests (abnormal distribution). Statistical comparisons
of the means of multiple (R3) groups were determined using repeated-
measures one-way ANOVA (normal distribution) or Kruskal Wallis nonpara-
metric analyses (abnormal distribution).
Additional procedures are described in Supplemental Experimental
Procedures.ancer Cell 22, 466–478, October 16, 2012 ª2012 Elsevier Inc. 475
Figure 8. Therapeutic Suppression of
Gastric Tumorigenesis in gp130F/F Mice
Treated with a TLR2 Blocking Antibody
(A) qPCR of Tnfa and Cxcl2 gene expression was
performed on antral gastric tissue of 12-week-old
gp130F/F mice that were untreated (gray bars) or
pretreated with either OPN-301 (white bars) or
isotype (black bars) control antibodies for 30 min
prior to administration with Pam3Cys over 6 hr.
Expression data from at least two samples per
time point and treatment group are shown
following normalization for 18S and are presented
from replicate analysis as the mean ± SEM fold
induction. *p < 0.05.
(B) Representative appearance of stomachs from
22-week-old gp130F/F mice treated twice weekly
over 10 weeks with either OPN-301 or isotype
control antibodies. Arrows indicate macroscopi-
cally visible tumors >4 mm in diameter. Fundic (f)
and antral (a) stomach regions are labeled.
(C and D) Scatter plots depicting the total mass
(grams) of gastric tumors (C), as well as the inci-
dence of tumors (D), from 22-week-old gp130F/F
mice treated twice weekly over 10 weeks with
either OPN-301 or isotype control antibodies. Data
for each group are expressed as the mean ± SEM.
*p < 0.05.
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